Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SBI-087 in subjects with Systemic Lupus Erythematosus (SLE).
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
Collaborators
NCT07330245 · Lupus Erythematosus, Systemic
NCT07015983 · Lupus Erythematosus, Systemic, Lupus Nephritis
NCT07438496 · Lupus Erythematosus, Systemic
NCT06673043 · Lupus Erythematosus, Systemic
NCT05648500 · Lupus Erythematosus, Systemic
Arthritis & Rheumatology Care Center
South Miami, Florida
Miami Research Associates
South Miami, Florida
MRA Clinical Research
South Miami, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions